Molecular Biology Program
The John Maciejowski Lab
Advanced whole genome sequencing and computational approaches have uncovered staggeringly complex alterations in cancer genomes such as chromosome shattering, trains of coordinated translocations, and clustered mutations. Despite the recognition that these variations can enable neoplastic growth and facilitate clonal evolution, the underlying causes are often unknown. Our long-term goals are to understand the pathways leading to clustered mutation and chromosome rearrangements and to determine how engagement of these pathways impacts cancer progression, heterogeneity, and response to therapy. We focus much of our effort on telomere crisis, which can act as a major source of the instability observed in cancer genomes. To achieve our research goals we are taking a multi-disciplinary approach that includes live-cell imaging, genetic, and genomics-oriented methodologies.
John Maciejowski, PhD
- Molecular biologist John Maciejowski studies the causes of complex chromosome rearrangements and the patterns of hypermutation that shape cancer genomes.
- PhD, Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center
- Email Address
- NIH Pathway to Independence Award (2016)
- Tri-Institutional Breakout Prize for Junior Investigators (2016)
- Regeneron Prize for Creative Innovation (2016)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
John Maciejowski discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.